Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical development of ND081 Kaken…
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company,…
